Bristol Myers-Squibb/AstraZeneca's Onglyza Officially Cleared For Europe
This article was originally published in The Pink Sheet Daily
Executive Summary
New DPP-4 inhibitor for diabetes passes noninferiority test against Merck's hugely popular Januvia.